Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medicines360 and Actavis plc announces FDA acceptance for filing of NDA for Levosert IUD


Monday, 21 Jul 2014 04:30pm EDT 

Medicines360 and Actavis plc:Says that U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360's New Drug Application (NDA) for Levosert (levonorgestrel), hormonal intrauterine contraceptive (IUC) for use by women to prevent pregnancy. 

Company Quote

265.39
1.64 +0.62%
19 Dec 2014